Evidence map›Paper›PMID 41449642›Full record

ReviewEuropean journal of haematology2026

Beyond PD-1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next-Generation Immune Strategies.

Santino Caserta, Enrica Antonia Martino, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Santino CasertaHematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy.
Enrica Antonia MartinoHematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy.
Mamdouh SkafiEmergency and Internal Medicine Department, Saint Joseph Hospital, East Jerusalem, Palestine.
Maria Eugenia AlvaroHematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy.
Antonella BruzzeseHematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy.
Nicola AmodioDepartment of Experimental and Clinical Medicine, University of Catanzaro, Catanzaro, Italy.
Eugenio LuciaHematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy.
Virginia OlivitoHematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy.
Caterina LabancaHematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy.
Francesco MendicinoHematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy.ORCID https://orcid.org/0000-0001-6339-632X
Ernesto VignaHematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy.
Fortunato MorabitoAIL Sezione di Cosenza, Cosenza, Italy.
Massimo GentileHematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy.ORCID https://orcid.org/0000-0002-5256-0726

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PD-1 inhibitors have reshaped the treatment landscape of classical Hodgkin lymphoma, yet a substantial proportion of patients exhibit primary or acquired resistance driven by tumor-intrinsic alterations, immunosuppressive microenvironmental signals, metabolic constraints, and EBV-mediated modulation. This review summarizes key mechanisms underlying PD-1 resistance and highlights emerging biomarkers-including early

Indexed as

Drug Resistance, NeoplasmHodgkin DiseaseImmune Checkpoint InhibitorsImmunotherapyProgrammed Cell Death 1 ReceptorBiomarkers, TumorHumansTumor MicroenvironmentBiomarkers, TumorImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptorclassic Hodgkin lymphomactDNAPD‐1PET

Identifiers

PMID41449642
PMCPMC12958791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.